Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | CHKA | P35790 | 6/20 | 0.55 |
| ▸ | FAAH | O00519 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MC4R | P32245 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29468844 | 1.00 | KDM4E (0.68) | KDM4ECHKAFAAHLMNAALDH1A1 | |
| SCHEMBL29173652 | 0.87 | CHKA (0.58) | KDM4ECHKAFAAHLMNAALDH1A1 | |
| SCHEMBL12891510 | 0.85 | ALDH1A1 (0.69) | KDM4ECHKALMNAALDH1A1HTT | |
| SCHEMBL29468778 | 0.83 | KDM4E (0.58) | KDM4ECHKAFAAHALDH1A1HTT | |
| SCHEMBL29468773 | 0.83 | KDM4E (0.55) | KDM4ECHKAFAAHALDH1A1HTT | |
| SCHEMBL10071720 | 0.82 | CHKA (0.56) | KDM4ECHKALMNAALDH1A1HTT | |
| SCHEMBL29468730 | 0.82 | KDM4E (0.53) | KDM4ECHKAFAAHALDH1A1HTT | |
| SCHEMBL2376586 | 0.81 | KDM4E (0.68) | KDM4EFAAHLMNAALDH1A1HTT | |
| SCHEMBL5503947 | 0.80 | LMNA (0.47) | KDM4ECHKALMNAALDH1A1HTT | |
| SCHEMBL1631404 | 0.80 | CHRM3 (0.64) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448921-A1 | ARYL INDOLE DERIVATIVES | MSD K.K. (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-20120022078-A1 | ARYL INDOLE DERIVATIVES | MSD K.K. (JP) | 2012-01-26 | — | — | US | disclosed |
| WO-2010117085-A1 | ARYL INDOLE DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022078-A1 | ARYL INDOLE DERIVATIVES | IDO1, NAT1, IDO2 | KDM4E 4044/4885CHKA 2500/4885FAAH 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.